Mizacorat
Small moleculeexperimental
Clinical trial activity
4 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2015 (NCT02512575)
Timeline
Indications
Mechanism of action
- Glucocorticoid receptorMODULATOR
NR3C1 modulator
Chemistry & pharmacology
Loading structure…
SMILES
CC(C)[C@H](NC(=O)C(C)(F)F)[C@H](Oc1ccc2c(cnn2-c2ccc(=O)n(C)c2)c1)c1ccccc1- Mol. weight
- 494.54 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4207852 ↗
Also known as
- azd9567
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04556760 | Phase 2 | Nov 26, 2020 | AstraZeneca, Parexel, Profil GmbH |
| NCT03368235 | Phase 2 | Jan 18, 2018 | AstraZeneca, Utrecht University |
| NCT02760316 | Phase 1 | May 2, 2016 | AstraZeneca, Parexel |
| NCT02512575 | Phase 1 | Nov 1, 2015 | AstraZeneca, Parexel |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 4 | 4 | 2 | 2015 |
| Parexel | For profit | 3 | 0 | 2 | 2015 |
| Profil GmbH | For profit | 1 | 0 | 1 | 2020 |
| Utrecht University | Academic/Hospital | 1 | 0 | 1 | 2018 |
4 organizations
Page 1 / 1